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Abstract: Abnormal aggregation of tau is the pathological hallmark of tauopathies including fron-
totemporal dementia (FTD). We have generated tau-transgenic mice that express the aggregation-
prone P301S human tau (line 66). These mice present with early-onset, high tau load in brain and
FTD-like behavioural deficiencies. Several of these behavioural phenotypes and tau pathology are
reversed by treatment with hydromethylthionine but key pathways underlying these corrections
remain elusive. In two proteomic experiments, line 66 mice were compared with wild-type mice
and then vehicle and hydromethylthionine treatments of line 66 mice were compared. The brain
proteome was investigated using two-dimensional electrophoresis and mass spectrometry to iden-
tify protein networks and pathways that were altered due to tau overexpression or modified by
hydromethylthionine treatment. Overexpression of mutant tau induced metabolic/mitochondrial
dysfunction, changes in synaptic transmission and in stress responses, and these functions were
recovered by hydromethylthionine. Other pathways, such as NRF2, oxidative phosphorylation and
protein ubiquitination were activated by hydromethylthionine, presumably independent of its func-
tion as a tau aggregation inhibitor. Our results suggest that hydromethylthionine recovers cellular
activity in both a tau-dependent and a tau-independent fashion that could lead to a wide-spread
improvement of homeostatic function in the FTD brain.
Keywords: mouse model; tau protein; frontotemporal dementia; proteomics; hydromethylthionine; LMTM
1. Introduction
Tauopathies, such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD),
are distinct neurodegenerative disorders with overlapping pathology. A common feature
is the deposition of abnormal tau aggregates [1–3] which, under physiological conditions
promotes microtubule assembly, stabilises axons and allows axonal branching and axonal
transport [4]. For FTD, cases are characterised by their pathology; most cases presenting
with either tau or TDP-43 pathology [5]. In the diseased brain, small oligomeric aggregates
of tau are formed initially, with subsequent accumulation of tau in paired helical filaments
(PHFs) and these changes contribute to synaptic dysfunction, microtubule collapse and
neuronal death [6]. While several mutations in the longest human CNS tau isoform
(htau40) appear to promote tau aggregation and have been associated with early onset
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) [7–10],
relatively little is known about how these mutations affect the global proteome. This work
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constitutes one of the first attempts to determine such global alterations in brain protein
expression as a result of drug treatment.
Clinical proteomics have been used for almost three decades to discover diagnostic markers
in neurodegenerative disorders (see [11–20]). These studies concentrated on AD and have used
brain tissue, cerebrospinal fluid and blood as substrates for analysis. Low reproducibility was
found between independent studies possibly due to technical variability, sample treatment
prior to proteomic analysis and because of heterogeneity of the patient cohort as a result of
failure to separate out their co-morbidities. The more recently applied endophenotype based
data correlation approach appears to be more reliable [16]. However, limited proteomic studies
are available for FTD (for review see [21–25]). For example, Hu and co-workers identified
151 differentially regulated proteins for FTD, but these only yielded 78% specificity for FTD
with TDP-43 pathology (FTD-TDP) over FTD with tau pathology (FTD-tau) [26]. By contrast,
Teunissen et al. reported 56 differentially regulated proteins, which is less than 4% of the 1914
identified proteins, and only 10 of these differed between those FTD cohorts characterised by
TDP-43 and tau pathologies [27]. Intriguingly, YKL-40 (a member of the glycosyl hydrolase
18 family with a role in inflammation) was increased in both forms of FTD, while catalase
was reduced, when compared to controls and patients with AD, dementia with Lewy bodies
or vascular dementia. Comparisons of CSF from AD or FTD patients with control subjects
yielded only few proteins that altered abundance specifically with disease status. A multi-centre
surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF)
study revealed 15 putative biomarkers in CSF of AD and FTD patients that were differentially
regulated [28]. Seven of these identified proteins (including cystatin C and chromogranin
A peptide) also differentiated between the two dementia disorders. However, the proteins
identified did not match those of previous studies using CSF samples [29,30], a finding which
was ascribed to their lower solubility and abundance in CSF compared to brain [31].
The majority of studies on brain tissue for FTD have focussed on cases with TDP-43
pathology and have examined extracts derived from prefrontal cortex or hippocampus
with more than 50 proteins changing abundance in the diseased brains (see [24] for a sum-
mary). Using laser capture microdissection, high resolution LC-MS/MS and labelling-free
quantitation methods, Gozal and colleagues confirmed 54 proteins selectively increased,
while 19 proteins out of a total of 1252 selectively decreased abundance in dentate gyrus
granule cells of patients with the ubiquitinated type of FTD [32]. Similarly, earlier work
by Schweitzer and colleagues on frontal cortex from FTD patients had returned 48 pro-
teins with matrix-assisted laser desorption/ionisation (MALDI) TOF that were of different
abundance in FTD patients relative to controls and functionally classified into cytoskele-
ton, metabolism, oxidative stress, proteolysis, signal transduction and others [33]. The
proteolytic enzyme ubiquitin C-terminal hydrolase L1 was included in this list and was
particularly reduced in a patient expressing the P301L mutation of FTDP-17 and may
explain how the mutation disrupts interactions of the C-terminal domain of tau with the
proteasome [34].
In experimental AD models, overexpression of human wild-type tau under the con-
trol of the neuronal enolase promotor followed by 2-DE of cortical tissue at 6 and 12
months yielded a total of 19 proteins changing in abundance [35]. These included se-
cernin 1, V-type proton ATPase subunit E1, glyceraldehyde 3-phosphate dehydrogenase,
dihydropyrimidinase-related protein 2, proteasome subunit alpha type-4, and NADH
dehydrogenase [ubiquinone] iron-sulphur protein 8. These proteins were increased at 6,
but decreased at 12 months, and for which neuroprotective roles were suggested.
For 3xTg AD mice, which overexpress tau carrying the P301L mutation and ß-amyloid
precursor protein carrying the Swedish double mutation, hippocampal tissue was studied
at 12 months of age with a focus on O-GlcNAcylated proteins. In this study, 14 differentially
expressed proteins that were O-GlcNAcylated were involved in glucose homeostasis, en-
ergy metabolism, cytoskeletal network and neurotransmission [36]. By contrast, oxidative
phosphorylation was the focus of another study using hippocampal tissue from 3xTg AD
mice. Sixty-four mitochondrial and nuclear proteins were differentially expressed [37].
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However, a clear link with tau expression remains elusive given the potential interaction
between amyloid and tau in these mice. A more appropriate FTD-like model therefore is es-
tablished through overexpression of P301S/L tau only. In a two-dimensional difference gel
electrophoresis (2D-DIGE) approach, spinal cord from 7-month-old mice was homogenised
and returned a total of 32 differentially regulated proteins; four of these proteins, heat
shock protein 27 (Hsp27), peroxiredoxin-6, apolipoprotein E, and latexin, were all enhanced
in astrocytes suggesting a neuroprotective function [38]. Similarly, heat shock proteins
were amongst the upregulated proteins in Tg4510 mice which also expressing human
tau carrying the P301S mutation [39]. These data strongly indicate the need for a more
comprehensive study of the brains of FTD models. We selected the line 66 (L66) mouse and
compared whole brain tissue with age-matched wild-type mice using two-dimensional
electrophoresis (2-DE) followed by nano liquid chromatography tandem mass spectrom-
etry (nano-LC-ESI-MS/MS). L66 has been extensively characterised behaviourally [40],
with respect to tau expression and localisation [41], in terms of cholinergic status and
inflammation [42] and in synaptic release of glutamate [43]. L66 mice overexpress the
largest human 2N4R isoform (441 amino acid residues) carrying aggregation-promoting
mutations P301S and G335D [40,44].
Prevention of tau aggregation is a valid therapeutic strategy since numerous stud-
ies have confirmed a correlation between the degree of tau aggregation and the sever-
ity of dementia [12,13,37,45]. The most promising approach, targeting the inhibition of
tau aggregation and its clearance, is based on methylthioninium chloride (MTC) and its
stably reduced form N,N,N′,N′-tetramethyl-10H-phenothiazine-3,7-diaminium bis (hy-
dromethanesulfonate) (leucomethylthioninium bis(hydromethanesulfonate; LMTM). LMT
has recently been assigned the International Nonproprietary Name “hydromethylthionine”,
recognising it as chemically and pharmacologically distinct from MTC. The methylthion-
inium (MT) moiety can exist in oxidised (MT+) and reduced (LMT) forms and we have
reported recently that LMTM blocks tau aggregation and propagation in vitro [46], reverses
behavioural deficits and tau pathology in mice [47] and hydromethylthionine has phar-
macological activity on brain structure and function in both AD [48] and FTD [49]. In
addition to its effect as a tau aggregation inhibitor, MTC has several beneficial effects on
pathways relevant to neurodegenerative disorders [50]. It induces mitochondrial biogene-
sis [51], mitochondrial complex I-IV activity [52–56], activates NRF2-mediated antioxidant
response [57], inhibits microglial activation [58] and facilitates tau clearance by promoting
the ubiquitin–proteasome-system and autophagy [59,60]. These data confirm that MT acts
on multiple intracellular systems. Understanding the pathways activated in L66 by LMTM
would therefore instruct on the potential treatment benefit and aid in the development
of novel therapeutic strategies. In this study, we report proteomic analysis of L66 mice
treated with two dosing regimes of LMTM, an approach that has not been available in
other experimental models or in humans.
2. Materials and Methods
2.1. Animals
Transgenic mice are described in detail elsewhere [40]. Briefly, L66 mice overexpresses
the largest human CNS tau isoform (htau40 with 441 amino acid residues), with the
mutations P301S and G335D, under the control of the mouse Thy1-promotor. These mice
express early onset, high tau load in the brain globally and their genetics, behavioural
and histopathological phenotypes are reminiscent of frontotemporal dementia. A detailed
characterisation of these transgenic mice was reported earlier and male and female mice
show similar behavioural and pathological phenotypes [40–42].
Female homozygous transgenic L66 and wild-type NMRI litters were bred commer-
cially in isolators (Harlan (now Envigo), Hillcrest, UK) and delivered by truck at least 10
days before experimental work commenced. They were housed genotype specifically in
small colonies up to five animals in open housing (Type III, 382 mm × 220 mm) with corn
cob bedding and paper strips and cardboard tubes as enrichment (cleaning rota once per
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week). Holding rooms were on constant temperature (20–22 ◦C), humidity (60–65%), and
air exchange rate (17–20 changes/h) with 12 h light/dark cycle (lights on at 6 am, simulated
dawn). Animals had free access to food and water. All animal experiments were performed
in accordance with the European Communities Council Directive (63/2010/EU) and a
project licence with local ethical approval under the UK Animals (Scientific Procedures)
Act (1986) and comply with the ARRIVE guidelines 2.0 [61]. Brains were sent to Berlin
(Charité) via courier on dry ice.
For proteomics and protein-based studies, different female mouse cohorts were used
for two separate experiments: Experiment 1: untreated wild-type NMRI mice and L66
mice (8–12 per group; Figure 1A); Experiment 2): vehicle and LMTM-treated L66 mice
(11–14 per group; Figure 1B). A third independent cohort (9–13 mice per group, including
NMRI and L66, treated with vehicle/LMTM) was used for histopathology examinations.
Animals were allocated to experimental groups based on their starting body weight with
equal average body weight for each group.
Figure 1. Study design for proteomics analyses. Proteomics analyses were conducted in (A) untreated
wild-type and L66 mice, to identify proteins changing due to tau over-expression (experiment 1), and
(B) in vehicle- or LMTM-treated L66 mice, to identify the effect of LMTM (experiment 2).
2.2. Drugs and Treatment Cohorts
N,N,N’,N’-Tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) (LMTM)
was supplied by TauRx Therapeutics Ltd., Aberdeen UK. The doses of LMTM are expressed in
terms of free methylthioninium (MT) base per animal body weight (mg MT/kg). For vehicle
and LMTM treatments, 4-months old mice were assigned to treatment cohorts and dosed
with vehicle or LMTM for 8 weeks (seven days per week) and sacrificed at 6 months of age.
Compounds were administered in the morning via oral gavage, at a volume of 5 mL/kg body
weight. LMTM was dissolved in vehicle (argon-sparged deionised water) and administered
within 20 min of dissolution. Treatment regime and dose selection were based on successful
lowering of tau pathology and on behavioural phenotype rescue in tau-transgenic mice [47].
Only L66 tau mice were exposed to treatment with LMTM to focus on the correction/alteration
of disease-relevant proteins.
2.3. Sample Collection
At the age of 6 months, we administered the last vehicle/drug and sacrificed mice by
cervical dislocation one hour later. Brains (without olfactory bulbs) were removed rapidly,
washed in cold 30 mM 2-ethane sulphonic acid/60 mM sodium fluoride buffer and either
snap frozen in liquid nitrogen for proteomics and immunoblotting analyses (two groups of
7–10 mice per group for genotype related effects and three groups of 11–14 mice per group
for LMTM related effects) or fixed for 24 h in formalin, embedded in paraffin and sectioned
on a rotary microtome (Microm HM325, Leica Biosystems, Nussloch, Germany) at 5µm for
histopathology (four groups of 9–13 mice per group).
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2.4. Immunohistochemistry and Neuronal Cell Counting
Coronal brain sections, 5 µm thick and mounted onto glass slides (three sections per slide),
were deparaffinised, boiled for antigen retrieval in 10mM citric buffer and then incubated
in 0.3% (v/v) hydrogen peroxidase solution. Sections were blocked for 20 min in blocking
solution (0.1% (w/v) BSA in PBS), incubated in primary antibody (NeuN Clone A60, Merck
Millipore, Burlington, MA, USA, diluted 1:11,000), followed by incubation in biotinylated
goat anti-mouse IgG secondary antibody (Dako Denmark, Glostrup, Denmark). Primary and
secondary antibodies were diluted in blocking solution and reactions were conducted for 1 h at
room temperature (RT). Sections were then developed with diaminobenzidine solution (Dako
Denmark) and embedded in Neo-Mount (Merck Millipore, USA). Images were taken using a
light microscope at a 200×magnification (Carl Zeiss, Jena, Germany) and quantification was
conducted by an investigator, blinded with respect to the genotype and the treatment. Neurons
expressing NeuN were counted manually in a fixed area in hippocampal CA1, CA3 and dentate
gyrus, all at Bregma level −3.16 ± 0.36, as well as in primary motor cortex (MC) at Bregma
level 0.74 ± 0.36 [62].
2.5. Urea Protein Extraction
For 2-DE, crushed frozen tissue from whole brain (including cerebellum and excluding
olfactory bulb) was incubated for 45 min in six volumes of extraction buffer (7 M urea, 2 M
thiourea, 2% ampholyte 2-4, 70 mM DTT, 25 mM Tris/HCl pH 8.0, 50 mM KCl, 3 mM EDTA,
2.9 mM benzamidine and 2.1 µM leupeptin) and centrifuged for 45 min at 16,000× g and RT.
The urea extract (supernatant) was transferred to new tubes and the protein concentration
determined with Bradford reagent (Carl Roth, Karlsruhe, Germany) according to standard
procedures.
2.6. 2-DE and Comparative Gel Analysis
Large scale 2-DE (23 cm × 30 cm × 0.75 mm) and image analyses were conducted
as described before [63]. Protein extracts (100 µg) were loaded at the anodic side of the
isoelectric focusing (IEF) gel and focused in a gradient between pH 2 and 11 at 8500 Vh (1 h
at 100 V, 1 h at 200 V, 16.5 h at 400 V, 1 h at 600 V, 30 min at 1000 V, 10 min at 1500 V, 10 min at
2000 V). After equilibration in Tris-SDS-DTT solution (50mM Tris pH 6.8, 3% (w/v) SDS and
1% DTT (w/v)), IEF gels were placed on top of a 15% glycine-SDS second dimension gel and
separated at 4 ◦C in Tris-glycine buffer (25mM Tris and 192 mM glycine; pH 6.8). Gels were
fixed overnight in 50% (v/v) ethanol and 10% (v/v) acetic acid and silver stained [64]. Gel
images with 150 dpi resolution were analysed with the Proteomweaver software version
3.0.9.9 (BioRad, Feldkirchen, Germany) according to the manufacturer’s instructions. The
software includes an integrated statistics tool to automatically normalise the data set and
calculate average spot intensities, regulation factors (=spot intensity ratio) and p-values.
Briefly, spots were automatically detected and spot intensities were then normalised to
total intensity of all spots (on one gel) and matching was carried out first inside groups
and then between groups. Inaccurate spot identification was corrected manually. Spots
were considered to be regulated when the relative spot density was significantly different
(p < 0.05) and if the spot was present in at least 80% of gels in each study group. No
further cut-off or post-hoc analyses were applied to the data and all significantly regulated
spots with the above-described behaviour were subjected to MS analysis. For the genotype
analysis (experiment 1), wild-type NMRI mice were set as reference group, while for
LMTM-associated effects (experiment 2), vehicle-treated L66 mice served as reference.
2.7. Trypsin Digestion and MS-MS Analyses for Protein Identification
Proteins (120 µg) were separated as stated above by large scale preparative 2-DE gels
(23 cm × 30 cm × 1.5 mm) and gels were thereafter stained with MS-compatible silver [65].
All significantly different protein spots were excised from preparative gels and digested
using 200 ng trypsin. Digestion was conducted overnight at 37 ◦C and the enzymatic
reaction was terminated the next day with formic acid. Tryptic peptides were analysed by
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nanoLC-ESI-MS/MS. The MS system consisted of an Agilent 1100 nanoLC system (Agilent,
Waldbronn, Germany), PicoTip electrospray emitter (New Objective, Littleton, MA, USA)
and an Orbitrap XL mass spectrometer (Bruker, Bremen, Germany).
After trapping and desalting the peptides on an enrichment column (Zorbax SB C18,
0.3 mm × 5 mm, Agilent, Germany) using 1% (v/v) acetonitrile and 0.5% (v/v) formic
acid for five minutes, peptides were separated on a Zorbax 300-SB-C18 column (75 µm ×
150 mm, Agilent, Germany) within 40 min, using a formic acid (0.1%) acetonitrile (5–40%)
gradient. The precursor ion was sent into gas filled collision cell for high energy collisional
dissociation. The fragment ions were sent to C-trap and transferred to orbitrap for analysis
Raw spectra files were generated by Xcalibur 2.1 (Thermo Fisher Scientific, Waltham,
MA, USA), uploaded to the MaxQuant platform (version 1.5.1.2, Max Planck Institute of
Biochemistry, Martinsried, Germany) and searched against a UniProtKB mouse protein
data base (downloaded from www.uniprot.org in December 2015). The MaxQuant software
allows protein identification and label-free quantification (LFQ; based on peak intensities
of spectra). The search settings were orbitrap as instrument, trypsin as enzyme and two
missed cleavages were allowed, Carbamidomethyl (C) was set as fixed modification and
Acetyl (protein N-term), Oxidation (M) and Deamidation (NQ) as variable modification.
The peptide tolerance was set to 5ppm, the MS/MS match tolerance to 0.5 Da, the peptide
spectral matches false discovery rate (FDR) and the protein FDR to 0.01. Further, the site
decoy fraction was set to 0.01, the minimal peptide length to 7, the minimal number of
matched peptides was 1 and the minimal score for peptides was 40.
In a case where the LFQ intensity of the first hit being >70% then only the first hit is
reported. In a case where the LFQ intensity of the first hit is <70% and the LFQ intensity of
the second hit >10% then the second hit is reported as well. For raw 2-DE and MS results,
see Supplementary Table S1; for annotated peptide spectra for protein identification based
on one single peptide, see Supporting Information.
2.8. Generation of Expression Heatmaps, Protein Classification and Pathway Analyses
All identified proteins were clustered according to their expression pattern using the
heatmapper online tool (www.heatmapper.ca, accessed on 30 March 2020) with average linkage
clustering and the Euclidean distance measurement method. For the generation of these
expression heatmaps, numerical information uploaded are transferred to z-scores (number of
standard deviation) and the average over all groups was build (NMRI and L66 for Experiment
1; L66 vehicle, L66 15 mg and L66 45 mg for Experiment 2). The z-scores were then assigned a
colour depending on their relative location to the population’s average: the average is shown in
black; values below the average are displayed red, while values above the average are displayed
green. The colour intensity indicates the distance to the population’s average (dark colours
being closer to the average than light colours). Further, we classified these proteins according
to biological processes using the Panther classification system database (www.pantherdb.org,
accessed on 30 March 2020). For pathway analyses, the Ingenuity Pathway Analysis tool
(IPA, version 01.04, Ingenuity Systems (now Qiagen Silicon Valley), Redwood City, CA, USA)
was used and the search limited to networks in nervous system of mammals with known
relationships between proteins. Networks were automatically assigned based on the probability
of protein matches and contrasted against chance. On the basis of altered pathways the software
predicts putative upstream regulators.
2.9. SDS-Page and Immunoblotting
The urea protocol from above was used to extract proteins for immunoblotting re-
placing the ampholytes with distilled water. Twenty µg protein per lane were separated
by SDS-PAGE using stain-free gradient gels (Bio-Rad, Germany) in Tris-glycine-buffer
(pH 8.3) containing 192 mM glycine, 25 mM Tris and 0.9% (w/v) SDS. Proteins were then
transferred for 30 min at 5V to a PVDF membrane by semi-dry blotting in Towbin buffer
pH 8.3 (200 mM glycine, 25 mM Tris, 0.1% (w/v) SDS and 20% (v/v) methanol). Thereafter,
membranes were blocked at RT for 1 h in blocking solution (4% (w/v) BSA in TBS with
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0.2% (v/v) Tween-20), incubated overnight at 4 ◦C in primary antibody, washed 3 times in
TBS-T and incubated for 1 h (RT) in appropriate secondary antibody conjugated to HRP
(Dako, Denmark; goat anti-rabbit IgG, goat anti-mouse IgG and rabbit anti-goat IgG diluted
1:5000 in blocking solution). After washing 3 times in TBS-T, membranes were overlaid
with ECL solution (GE Healthcare, Chicago, IL, USA) and chemiluminescent signals were
detected with the ChemiDoc™ MP imager (Bio-Rad, Feldkirchen, Germany). Primary
antibodies used were: AKT (#9272; 1:5000), p-Ser473 AKT (#4058; 1:1000), Erk1/2 (#4695;
1:1000), pThr202/Tyr204 Erk1/2 (#9101; 1:1000), CaMKII (#3362; 1:1000), pThr286 CaMKII
(#12716; 1:1000), Synapsin-2 (#85852; 1:10,000), α-synuclein (#4179; 1:2000), TrkB (#4603;
1:1000), P70S6K (#9202; 1:1000), pP70S6K (#9206; 1:5000), 4E-BP1 (#9452; 1:1000), p4E-BP1
(#9459; 1:1000), GSK-3α (#4337; 1:1000), p GSK-3α (#9316; 1:1000), GSK-3β (#12456; 1:1000)
and p GSK-3β (#5558; 1:1000) all from Cell Signaling Technology Europe, Frankfurt am
Main, Germany. PSD95 (ab12093; 1:1000) and syntaxin (ab112198; 1:5000) were purchased
from Abcam (Cambridge, UK). Synapsin-1 (#106001; 1:5000), synaptophysin-1 (#101002;
5:1000) and VAMP2 (#104202; 5:1000) were from Synaptic Systems, Goettingen, Germany.
SNAP-25 (#805001; 1:1000) was purchased from BioLegend, San Diego, CA, USA. BDNF
(#MABN79; 1:500) was from Merck Millipore (USA). All primary antibodies were diluted
in blocking solution. Densitometric quantification was performed using the Image Lab
software version 5.0 (Bio-Rad) and data were normalised to stain free total protein loading.
Blots for raw data are shown in the Supporting Information.
2.10. Data Analyses
Proteomics data were analysed by using integrated statistics tools of the Proteomweaver,
The MaxQuant and the IPA software following the parameters indicated above and no
further post-hoc analyses were applied to the data. Immunoblotting and immunohis-
tochemistry data are expressed as group mean and standard error (S.E.) and statistical
analysis was conducted using analysis of variance (ANOVA) with the Bonferroni multiple
comparison correction post-hoc test or using the unpaired t-test if appropriate (GraphPad
Prism software version 6.00; GraphPad Software Inc., San Diego, CA, USA) and differences
were considered significant at p < 0.05.
3. Results
An LMTM regime similar to the one used in the current study was reported earlier
to significantly lower tau pathology in multiple brain regions and to correct behavioural
abnormalities seen in L66 mice [47]. We have now in an independent study treated L66
mice with a similar LMTM regime and conducted a hypothesis-free proteomics study to
identify key pathways underlying these corrections.
Our large scale 2-DE protocol detected an excess of 2000 spots on average per mouse
(Figures 2 and 3). A representative 2-DE protein pattern for L66 against wild-type in
experiment 1 (Figure 2 shows an example gel image for a wild-type mouse) revealed
71 spots (=123 protein species; see Figure 4A) that were differentially abundant between
genotypes (p < 0.05). In contrast, due to the administration of LMTM to L66 (Figure 3 shows
an example gel image of a L66 vehicle-treated mouse), 433 spots (=657 protein species, see
Figure 4A) were differentially abundant in experiment 2. Seventeen spots (=27 protein
species) were common to both analyses (see Venn diagram, Figure 4A). The total of 487
spots (71 + 433 − 17 common to both groups) represent 753 regulated protein species [66],
as confirmed by MS. Supplementary Table S1 shows in detail which spots correspond to
which protein species, taking into consideration the LFQ inclusion criteria stated in the
Methods section.
Based on the Panther classification data base, altered proteins were organised into biological
processes. Of the proteins dysregulated in L66 (vs. wild-type), 28% were metabolic, 12%
related to stress response and around 28% exerted cell structure/microtubule stabilisation
and neuronal development/neurotransmission functions (Supplementary Figure S1A). Almost
27% of all proteins changing due to LMTM exerted metabolic functions, 6% were underlying
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the stress response, and more than 40% are involved in various neuronal function processes
(Supplementary Figure S1B).
A greater resolution of these protein activities was gained through Ingenuity Pathway
Analysis (IPA). IPA applies algorithms to establish a meaningful order and mechanistic links in a
large biological data set based on published data and the output is presented as cellular functions
(Table 1), intracellular pathways (Table 2), putative diseases (Table 3) and upstream regulators
(Table 4). Cellular functions linked to the observed protein changes were related to synaptic
transmission, e.g., synthesis of neurotransmitter, release/recycling/quantity of synaptic vesicles,
size/quantity of postsynaptic density, loss/quantity of dendrites, mitochondria and to formation
of amyloids (tau-filaments, Aß-plaques and other inclusion bodies, see Table 1). Pathways
most prominently affected relate to neurotransmission and synapse integrity including axonal
guidance signalling, p70S6K and PI3K/AKT signalling, mitochondrial function, NRF2-mediated
stress responses, clathrin-mediated endocytosis and protein ubiquitination (see Table 2 and
Supplementary Figures S2–S5). These proteins also play a role in AD, PD, cognitive impairment
and neurodegeneration (Table 3). It is apparent from these tables that protein alterations
observed for LMTM were largely not dose dependent for the dose range applied and further
protein quantification analyses were conducted for the 15 mg/kg dose cohort.
Table 1. Summary of significant hits for cellular functions identified using IPA Core Analysis. The cellular functions are
significantly altered due to tau overexpression, to LMTM treatment or both. Significant alterations were found by comparing our
proteomics data with the Ingenuity Knowledge Base. The cellular functions are named and corresponding p-values are given.
p-Value
FUNCTIONS
L66 vs. L66 (15mg/kg MT) L66 (45mg/kg MT)
Wild-Type Controls vs. L66 (Vehicle Control) vs. L66 (Vehicle Control)
Genotype
Patterning of dendrites 3.63 × 10−4 - -
Abnormal quantity of synaptic vesicles 7.08 × 10−4 - -
Long-term potentiation 6.31 × 10−3 - -
Quantity of dendrites 7.08 × 10−3 - -
Excitation of spiny neurons 1.20 × 10−2 - -
Quantity of postsynaptic density 1.20 × 10−2 - -
Elongation of axons 1.70 × 10−2 - -
Synthesis of dopamine 1.82 × 10−2 - -
Synthesis of L-glutamic acid 1.82 × 10−2 - -
Loss of hippocampal neurons 3.63 × 10−2 - -
Maturation of synaptic vesicles 3.63 × 10−2 - -
Release of neurotransmitter 4.57 × 10−2 - -
Genotype and LMTM
Endocytosis of synaptic vesicles 6.31E x 10−7 7.94 × 10−7 8.71 × 10−8
Transport of synaptic vesicles 2.82 × 10−6 3.47 × 10−6 8.91 × 10−7
Morphology of presynaptic terminals 7.41 × 10−5 1.86 × 10−2 2.09 × 10−2
Recycling of synaptic vesicles 3.47 × 10−4 6.92 × 10−5 7.24 × 10−6
Density of dendritic spines 1.20 × 10−2 2.95 × 10−3 4.79 × 10−3
Synaptic transmission of neurons 1.45 × 10−2 6.76 × 10−4 1.20 × 10−3
Size of postsynaptic density 1.82 × 10−2 3.47 × 10−4 4.27 × 10−4
Neurotransmission 2.82 × 10−2 7.41 × 10−6 2.29 × 10−5
Loss of dendrites 3.02 × 10−2 3.39 × 10−3 4.07 × 10−3
Synaptic depression 4.17 × 10−2 5.62 × 10−4 1.12 × 10−3
Synaptic transmission 4.27 × 10−2 3.39 × 10−6 1.00 × 10−5
LMTM
Size of neurons - 1.74 × 10−5 3.80 × 10−5
Association of synaptic vesicles - 3.47 × 10−4 4.27 × 10−4
Formation of cellular inclusion bodies - 6.61 × 10−4 1.15 × 10−4
Neurodegeneration of axons - 9.77 × 10−4 1.74 × 10−3
Swelling of mitochondria - 2.04 × 10−3 2.45 × 10−3
Microtubule dynamics - 2.51 × 10−3 5.01 × 10−3
Size of axons - 3.39 × 10−3 4.07 × 10−3
Depolarisation of mitochondria - 3.39 × 10−3 4.07 × 10−3
Abnormal morphology of axons - 6.03 × 10−3 3.55 × 10−2
Production of reactive oxygen species - 8.71 × 10−3 1.15 × 10−2
Formation of amyloid-beta plaques - 1.15 × 10−2 1.38 × 10−2
Formation of tau filament - 1.86 × 10−2 2.09 × 10−2
Ubiquitination of protein - 1.86 × 10−2 2.09 × 10−2
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Table 2. Summary of significant hits for canonical pathways identified using IPA Core Analysis. The pathways are
significantly altered due to tau overexpression, to LMTM treatment or both. Significant alterations were found by linking
our proteomics data with the Ingenuity Knowledge Base. The pathways linked to protein changes are named and
corresponding p-values are given. The highlighted pathways (bold) are of specific interest and are discussed in detail in the
text and in Supplementary Figures S2–S5.
p-Value
PATHWAYS
L66 vs. L66 (15mg/kg MT) L66 (45mg/kg MT)
Wild-Type Controls vs. L66 (Vehicle Control) vs. L66 (Vehicle Control)
Genotype
Protein kinase A signalling 3.89 × 10−4 - -
GnRH signalling 5.50 × 10−3 - -
Gap junction signalling 1.07 × 10−2 - -
Aspartate biosynthesis 1.82 × 10−2 - -
IGF-1 signalling 2.04 × 10−2 - -
Cell cycle 2.34 × 10−2 - -
Synaptic long term potentiation 2.45 × 10−2 - -
Wnt/Ca2+ pathway 2.45 × 10−2 - -
fMLP signalling in neutrophils 2.95 × 10−2 - -
ERK5 signalling 4.68 × 10−2 - -
Genotype and LMTM
Gluconeogenesis I 3.63 × 10−6 4.90 × 10−10 2.45 × 10−11
Glycolysis I 1.66 × 10−4 1.62 × 10−13 4.47 × 10−7
TCA cycle II (eukaryotic) 1.66 × 10−4 1.00 × 10−11 2.45 × 10−11
P70S6K signalling 5.13 × 10−4 9.55 × 10−3 1.51 × 10−2
Mitochondrial function 1.48 × 10−3 9.55 × 10−12 5.50 × 10−11
Huntington’s disease signalling 1.86 × 10−3 1.12 × 10−6 8.91 × 10−7
Unfolded protein response 2.69 × 10−3 1.05 × 10−2 1.48 × 10−2
Clathrin-mediated endocytosis signalling 2.82 × 10−3 6.76 × 10−7 6.46 × 10−8
14-3-3-mediated signalling 4.07 × 10−3 1.86 × 10−3 3.31 × 10−3
Glutamate biosynthesis II 1.20 × 10−2 3.72 × 10−2 4.07 × 10−2
NRF2-mediated oxidative stress response 1.66 × 10−2 3.98 × 10−6 1.00 × 10−8
Glutamate degradation II 1.82 × 10−2 1.02 × 10−3 1.26 × 10−3
PI3K/AKT signalling 2.51 × 10−2 1.26 × 10−2 5.50 × 10−3
Regulation of EIF4 and P70S6K signalling 4.07 × 10−2 2.00 × 10−2 3.09 × 10−2
Tight junction signalling 5.00 × 10−2 4.27 × 10−2 2.29 × 10−2
LMTM
Aspartate degradation II - 5.89 × 10−7 8.71 × 10−7
Oxidative phosphorylation - 3.55 × 10−6 8.51 × 10−6
Protein ubiquitination pathway - 9.33 × 10−5 6.61 × 10−5
RhoA signalling - 9.55 × 10−5 3.63 × 10−5
Parkinson’s signalling - 1.82 × 10−4 2.63 × 10−4
Fatty acid α-oxidation - 6.61 × 10−4 1.00 × 10−2
NADH repair - 1.02 × 10−3 1.26 × 10−3
Signalling by Rho family GTPases - 1.20 × 10−3 2.24 × 10−4
PPARA/RXRA activation - 1.78 × 10−3 1.12 × 10−2
Glutathione-mediated detoxification - 3.02 × 10−3 4.92 × 10−7
Telomerase signalling - 4.57 × 10−3 7.41 × 10−3
Super pathway of methionine degradation - 6.76 × 10−3 8.71 × 10−3
Regulation of actin-based motility by Rho - 1.12 × 10−2 3.63 × 10−3
Semaphorin signalling in neurons - 1.32 × 10−2 1.82 × 10−2
VEGF signalling - 1.32 × 10−2 4.47 × 10−3
Neuregulin signalling - 1.38 × 10−2 2.04 × 10−2
Axonal guidance signalling - 1.70 × 10−2 1.66 × 10−2
PPAR signalling - 1.70 × 10−2 2.45 × 10−2
Super pathway of citrulline metabolism - 1.70 × 10−2 2.09 × 10−2
Rho-GDI signalling - 2.14 × 10−2 1.00 × 10−3
GABA receptor signalling - 2.88 × 10−2 3.89 × 10−2
Xenobiotic metabolism signalling - 3.09 × 10−2 2.51 × 10−3
EIF2 signalling - 3.89 × 10−2 5.75 × 10−2
Actin cytoskeleton signalling - 4.07 × 10−2 8.71 × 10−3
FAK signalling - 4.57 × 10−2 1.66 × 10−2
Integrin signalling - 8.13 × 10−2 5.01 × 10−2
RAC signalling - 9.55 × 10−2 4.37 × 10−2
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Table 3. Summary of significant hits for related diseases identified using IPA Core Analysis. The disorders are significantly altered
due to tau overexpression, to LMTM treatment or both. Significant alterations were found by linking our proteomics data with the
Ingenuity Knowledge Base. The diseases linked to protein changes are named and corresponding p-values are given.
p-Value
DISEASES
L66 vs. L66 (15mg/kg MT) L66 (45mg/kg MT)
Wild-Type Controls vs. L66 (Vehicle Control) vs. L66 (Vehicle Control)
Genotype Memory 3.63 × 10
−3 - -
Behaviour 2.95 × 10−2 - -
Genotype and LMTM Alzheimer’s disease 3.31 × 10
−4 3.39 × 10−3 2.24 × 10−3
Degeneration of brain 5.50 × 10−3 5.89 × 10−4 1.20 × 10−3
LMTM
Disorder of basal ganglia - 2.63 × 10−8 2.00 × 10−7
Progressive motor neuropathy - 9.12 × 10−8 5.37 × 10−8
Neuromuscular disease - 4.37 × 10−7 2.63 × 10−6
Movement disorders - 6.17 × 10−7 1.10 × 10−6
Parkinson’s disease - 8.71 × 10−7 2.29 × 10−6
Neurodegeneration of hippocampus - 9.12 × 10−3 1.10 × 10−2
Cognitive impairment - 2.75 × 10−2 2.69 × 10−3
Table 4. Summary of putative upstream regulators identified using IPA Core Analysis. These regulatory molecules are
significantly altered and upstream of pathways stated in Table 2.
UPSTREAM L66 vs. L66 (15mg/kg MT) L66 (45mg/kg MT)







PLCB4 5.89 × 10−3 - - - - -
Sept5 1.17 × 10−2 - - - - -
ZNF746 1.74 × 10−2 - - - - -
AKT1 2.34 × 10−2 - - - - -
SLC18A3 2.34 × 10−2 - - - - -
AGRP 2.88 × 10−2 - - - - -
CDK5 3.47 × 10−2 - - - - -
CDK5R1 3.47 × 10−2 - - - - -
NOS2 3.98 × 10−2 - - - - -
MAPT 1.35 × 10−14 - 4.90 × 10−38 - 2.75 × 10−37 -
Genotype and LMTM
PSEN1 1.05 × 10−11 - 9.12 × 10−32 - 5.75 × 10−33 -
APP 6.31 × 10−11 - 2.14 × 10−31 - 1.45 × 10−30 -
HTT 1.41 × 10−7 - 1.10 × 10−9 - 3.89 × 10−8 -
SNCA 2.95 × 10−4 - 9.12 × 10−10 - 2.63 × 10−9 -
YWHAG 5.01 × 10−4 - 4.57 × 10−3 - 5.50 × 10−3 -
FMR1 1.51 × 10−3 - 3.39 × 10−6 - 6.61 × 10−6 -
RTN4 1.91 × 10−3 - 6.46 × 10−3 - 9.12 × 10−3 -
MKNK1 1.48 × 10−2 - 3.16 × 10−6 - 7.76 × 10−6 -
HSF1 3.47 × 10−2 - 4.57 × 10−3 - 5.50 × 10−3 -
BDNF 3.89 × 10−2 −1.12 1.66 × 10−4 −0.92 4.37 × 10−4 −0.92
LMTM
MTOR - - 2.04 × 10−8 2.1 (active) 5.01 × 10−9 1.7 (active)
ADORA2A - - 3.63 × 10−8 −0.58 1.17 × 10−9 −1.1
SOD1 - - 2.04 × 10−5 - 2.45 × 10−4 -
E2F1 - - 2.24 × 10−3 - 3.47 × 10−3 -
PARK2 - - 1.05 × 10−2 - 1.26 × 10−2 -
ARX - - 1.78 × 10−2 - 1.95 × 10−2 -
EIF2B2 - - 1.78 × 10−2 - 1.95 × 10−2 -
MARK2 - - 1.78 × 10−2 - 1.95 × 10−2 -
MYO5A - - 1.78 × 10−2 - 1.95 × 10−2 -
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Figure 2. Master gel representing protein spots differentially abundant between genotypes. Average, large-scale 2-DE gel
pattern of brain proteins extracted with urea and stained with silver. All 71 protein spots varying between the genotypes
(wild-type and L66) were identified by MS and are highlighted by arrows in representative wild-type gel (artificial gel image
created by the Proteomweaver software that shows average spot intensities of the wild-type mouse cohort). Identification
numbers (spot IDs) correspond to numbering as provided in the Supplementary Table S1.
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Figure 3. Master gel representing protein spots regulated by LMTM. Average, large-scale 2-DE gel pattern of brain proteins
extracted with urea and stained with silver. All 433 protein spots varying due to LMTM treatment (L66 treated with either
vehicle or different doses of LMTM) were identified by MS and are highlighted by arrows in a representative vehicle-treated
L66 gel (artificial gel image created by the Proteomweaver software that shows average spot intensities of the vehicle-treated
L66 mouse cohort). Identification numbers (spots IDs) correspond to numbering as provided in the Supplementary Table S1.
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Figure 4. Spots and protein species differentially abundant between wild-type and L66 mice and regulated by LMTM. (A)
Venn diagram with overview of regulated proteins showing 71 spots (123 protein species) with different expression between
genotypes and 433 spots (657 protein species) regulated by LMTM (15 and 45 mg/kg). Seventeen spots (27 protein species)
were common to both analyses. (B) Heatmap for protein species density in L66 compared to wild-type control mice. (C)
Heatmap for protein species density in LMTM-treated L66 mice compared to vehicle-treated L66 mice.
3.1. Impact of Tau-Overexpression on the Neuroproteome in L66 Mice
The 123 protein species (71 spots from experiment 1) differentially regulated between
the two genotypes were clustered for low expression in wild-type and heightened expres-
sion in L66 and vice versa (heatmap, Figure 4B). Sixty-three proteins clustered in the first
category (red cluster in upper left quadrant), while 60 proteins clustered in the latter (green
cluster in lower left quadrant). These clusters include 16 of the 27 shared protein species
(intersection in the Venn diagram Figure 4A) which were increased in L66 (ATPA, HSP74,
DHE3, GHC1, KPYM, ANXA7, PACN1, STK36, ACADV, ODPA, HPLN1, ADDB, HSP74,
PCCA, NSF and IDHC, Figure 5A,B) and 11 protein species whose expression was lower in
L66 (GTPC1, 2 species of RN181, AATM, MP2K1, DYN1, PYGB, PFKAL, ACON, RABE1
and HXK1, Figure 5A,B).
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Figure 5. Protein species with LMTM dose-dependent regulation. (A,B) Twenty-seven protein species (17 spots) were
common between experiments 1 and 2. (A) Ten of these protein species (7 spots) were normalised by LMTM, (B) while
no clear effect was identified for the remaining (17 species in 10 spots). (C–E) Twenty-six protein species (22 spots) were
dose-dependently regulated with (C) stronger effect at higher dose (9 protein species downregulated and 2 upregulated),
(D) stronger effect at lower dose (5 protein species downregulated and 4 upregulated), (E) only 15mg/kg was effective
(6 protein species upregulated). (F) Eight further protein species were regulated at the functional level as they shifted
horizontally following LMTM treatment, implying post-translational modifications. §: p < 0.05 vs. wild-type, *: p < 0.05 vs.
L66-vehicle, #: p < 0.05 vs. L66-15LMTM.
Cells 2021, 10, 2162 15 of 30
3.2. LMTM-Dependent Protein Expression in L66 Mice
In Experiment 2, two cohorts of L66 mice were exposed to LMTM (15 and 45 mg/kg
daily for 8 weeks) and compared with a vehicle cohort. The 657 differentially regulated
protein species (433 spots) were clustered according to their expression level in L66 (z-score
created by heatmapper). The majority of these proteins (518 protein species = about 80%)
showed high abundance in the vehicle cohort (see green cluster in the upper left quadrant
of the heatmap Figure 4C), most of which were downregulated by both doses of LMTM.
About half of these proteins were lowered to the average expression level (black); the other
half was decreased below average expression (red). Other proteins (131 protein species =
about 20%) were at a low level of expression for vehicle-treated mice (see red cluster in the
lower left quadrant of the heatmap Figure 4C) but considerably upregulated in the 15 and
45 mg/kg LMTM cohorts (green).
Of particular interest are the 27 protein species (17 spots) that are dysregulated by
tau-overexpression and modulated by LMTM treatment (intersection in the Venn diagram
Figure 4A). Important are those proteins normalised after LMTM treatment (Figure 5A),
which include mitochondrial glutamate dehydrogenase (DHE3), mitochondrial glutamate
carrier (GHC1) and annexin 7 (ANXA7). Other proteins showed no clear direction in effect
(e.g., isocitrate dehydrogenase, IDHC, and aspartate aminotransferase, AATM; Figure 5B).
Out of the 657 LMTM-regulated protein species only 26 were regulated in a dose-dependent
fashion. These again clustered in three different regulation patterns: (i) stronger effect at higher
dose (9 protein species were downregulated: DYN1, PP1R7, RN181, ENOA, HSP7C, HNRPC,
HS74L, SAM50 and ATPA; and 2 upregulated: ATP5H and PPIA, Figure 5C); (ii) stronger effect
at lower dose (5 protein species were downregulated: PABP1, ATPB, SUCA, HSP74 and ATPG;
and 4 upregulated: HIBCH, ACTG, NECP1 and SPB6, Figure 5D); (iii) only 15mg/kg was
effective (ATPB, ATPA, CACP, BPHL, SNAB and SNAA, Figure 5E). These contained not only
heat shock proteins (e.g., HSP7C, HSP74), but also proteins with structural (DYN1, ACTG,
SNAA) and metabolic/energetic functions (ATPA, ATPB, ATPG).
In addition, eight spots were shifted horizontally following LMTM treatment (Figure 5F),
implying post-translational modifications (PTMs). NDUV1, KCRU, ALDOA, PSDE and RAM
were shifted toward a basic isoelectric point (pH), while VDAC1, SODM and PRDX6 became
more acidic, confirming the ability of LMTM to promote protein regulation at the functional
level. Both SODM and PRDX6 are important scavengers for reactive oxygen species and integral
parts of the NRF2 pathway (see below).
3.3. Tau-Dependent Pathway Rescue by LMTM
We have recently confirmed the enrichment of P301S tau in the synaptic compartment
of L66 mice [41]. Further, our pathway analyses suggests that overexpression of tau
leads to changes in synapses, and that these are modifiable by treatment with LMTM
(Table 1, middle section). Accordingly, among the 27 protein species dysregulated by tau-
overexpression and modulated by LMTM, several protein species have known functions in
synaptic/neurotransmission, e.g., DYN1, ADDB, ANXA7 and PACN1 (Panther database).
We therefore reverted to immunoblotting for quantification of selected proteins potentially
responsive to treatment with LMTM (15 mg/kg) in L66 mice. Both α-synuclein and VAMP2
expression were reduced in L66 mice (Figure 6A,B; p < 0.05), but only α-synuclein levels
were normalised in LMTM-treated cohorts (Figure 6C,D). PI3K/AKT involved in signal
transduction and the mTOR kinase P70S6K were significantly altered in line with the IPA
analyses (Table 2). This pathway is a known regulator of protein synthesis, cell survival
and proliferation [67,68] and may induce the dysregulation of synaptic structural proteins.
The activity of AKT as upstream regulator of mTOR was significantly lowered in L66 mice
and both mTOR kinases P70S6K and 4E-BP1 followed a similar trend (Figure 7A,B). This
may be explained in terms of a significant reduction in BDNF signalling and the lowered
downstream kinase TrkB in L66 mice (Figure 7A,B and, additionally, Table 4 for BDNF),
which impinge on the AKT pathway. Taken together, an overall significant decrease in
the PI3K-AKT-mTOR pathway in L66 mice was confirmed (F(1,90) = 14.48; p = 0.0003).
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Intriguingly, all tau-related changes in the AKT-mTOR pathway were not normalised by
LMTM according to immunoblotting (Figure 7C/D), a result which is at odds with our
IPA analysis in which mTOR was activated following drug treatment (activation z-score
= 2.1, see Table 4). This finding may be due to different sensitivity limits between the
two methods. Since it is conceivable that the lack of trophic and structural support via
BDNF and α-synuclein increases synapse/cell loss [69,70], we next sought to confirm this
by quantitative counting of NeuN-immunoreactive neurons in tau-rich cortical areas and
comparing genotypes and drug cohorts. Relative to wild-type, there was a reliable loss of
principle cells in hippocampal CA1 (Figure 8A–C, F = 3.012, p = 0.040), CA3 (Figure 8D–F,
F = 3.405, p = 0.027), inner (F = 3.869, p = 0.017) and outer granule cell layer (F = 11.44, p <
0.0001) of the dentate gyrus (Figure 8G–I), as well as in the motor cortex (Figure 8J–L, F =
43.75, p < 0.0001). This is likely related to the reduction in BDNF activity (Figure 7), as the
cell loss was also not rescued despite relatively high doses of LMTM (45 mg/kg).
ERK and GSK-3 are crucial factors for neuronal survival and synaptic plasticity [71,72]. In
L66 mice, phosphorylation of ERK at threonine202/tyrosine204 and GSK-3ß at serine9, were
significantly increased and in CaMKII-α, which acts upstream of GSK-3, the phosphorylation
at threonine286 followed a similar direction (Figure 9A,B); no phosphorylation changes of
GSK-3α were detected. Exposure to LMTM only reversed pERK significantly (Figure 9C,D) but
reliably increased the phosphorylation of GSK-3ß, further underlining the specificity of LMTM
to normalise some but not all cell signalling cascades. It is reasonable to argue that failure to
re-establish the CaMKII-α/GSK-3ß activities offers an explanation for continued cell loss in L66
mice even after LMTM treatment.
Given our recent observation that oligomeric tau is enriched in vesicular fractions
derived from L66 mice [41], we explored mechanisms involved in release and recycling
of synaptic vesicles. Proteins of interest included clathrin, dynamins (DYN1, DYN2 and
DYN3), dynamin-like proteins (OPA1 and DNM1L), calcineurin (CANB1) and adaptor
protein complex 2 (AP-2 or AP2M1), which were all differentially expressed between L66
and wild-type mice. Multiple proteins of this clathrin-mediated endocytosis signalling
pathway (Supplementary Figure S2) were regulated by LMTM (Table 2); dynamin-1,
dynamin-3 and dynamin-like protein were all lowered, dynamin-1 and clathrin heavy
chain were significantly increased. These results strongly suggest that LMTM is capable
of normalising clathrin-mediated endocytosis and this mechanism might contribute to
improved neurotransmission and behavioural performance in these mice [43,47].
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Figure 6. Quantification of synaptic proteins in mice. Representative immunoblots for (A) wild-type and L66 mice and
(C) L66 mice treated with vehicle or LMTM (15 mg/kg). The proteins were separated by Tris-glycine SDS-PAGE and
immuno-detection conducted using the antibodies specified. (B,D) Densitometric quantification of these proteins was
normalised to total protein loading and values expressed as group mean ± S.E. Statistical analyses were conducted using
unpaired t-test for n = 8–12 (B) and n = 11–14 mice (D) per group. WT: wild-type. Original blot images are provided in the
Supporting Information.
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Figure 7. Quantification of BDNF/PI3K-AKT-mTOR activity in mice. Representative immunoblots for (A) wild-type
and L66 mice and (C) L66 mice treated with vehicle or LMTM (15 mg/kg). The proteins were separated by Tris-glycine
SDS-PAGE and immuno-detection conducted using the antibodies specified. (B,D) Densitometric quantification of these
proteins was normalised to total protein loading and values expressed as group mean ± S.E. Statistical analyses were
conducted using unpaired t-test and one-way ANOVA for n = 8–12 (B) and n = 11–14 mice (D) per group. WT: wild-type.
Original blot images are shown in the Supporting information.
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Figure 8. Neuronal cell counts between genotypes and in drug cohorts. Quantification of NeuN-immunoreactive neurons
by manual cell counting in hippocampal CA1 (A–C), hippocampal CA3 (D–F), the inner and outer granule cell layers of the
dentate gyrus (G–I), as well as in motor cortex (J–L) in wild-type (A,D,G,J) and L66 (B,E,H,K) mice. Loss of neurons in L66
mice was evident in hippocampal CA1 (C, p = 0.040) and CA3 areas (F, p = 0.027), in inner and outer GCL of the dentate
gyrus (I, p = 0.017 and p < 0.0001, respectively), as well as in the motor cortex (L, p < 0.0001). LMTM did not reverse this cell
loss in either area (C,F,I,L). Values are expressed as group mean ± S.E. Statistical analyses were conducted using one-way
ANOVA and Bonferroni corrected t-test for n = 9–13 mice per group. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001
compared to vehicle-treated wild-type mice. WT: wild-type.
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Figure 9. Quantification of ERK, GSK3 and CaMKII activity in mice. Representative immunoblots for (A) wild-type and L66
mice and (C) L66 mice treated with vehicle or LMTM (15 mg/kg). The proteins were separated by Tris-glycine SDS-PAGE
and immuno-detection conducted using the antibodies specified. (B,D) Densitometric quantification of the various proteins
was normalised to total protein loading and values expressed as group mean ± S.E. Statistical analyses were conducted
using unpaired t-test for n = 8–12 (B) and n = 11–14 mice (D) per group. WT: wild-type. Original blot images are shown in
the Supporting Information.
3.4. Tau-Independent Pathway Rescue by LMTM
Stress-induced-phosphoprotein 1 (STIP1), glutathione S-transferase Mu 5 (GSTM5),
glutathione S-transferase omega-1 (GSTO1), ubiquitin carboxyl-terminal hydrolase 14
(UBP14) and ferritin heavy chain (FRIH), were all increased in abundance by 1.3- to 2.2-fold
in LMTM-treated cohorts. In addition, PTMs have been suggested for both the mitochon-
drial superoxide dismutase (SODM) and peroxiredoxin-6 (PRDX6) as they were shifted
horizontally by LMTM, confirming its ability to promote protein regulation at a functional
level (Figure 5F). These proteins are all part of the NRF2 pathway (Supplementary Figure
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S3), which was both different between genotypes and responsive to LMTM treatment
(Table 2). Moreover, there is considerable crosstalk between NRF2 and mitochondria to
maintain mitochondrial redox homeostasis by providing important reactive oxygen species
scavengers such as glutathione peroxidase, glutathione reductase, SODM and peroxiredox-
ins [73]. It is therefore not surprising that the expression of proteins related to mitochondrial
function was altered in L66 and recovered following LMTM treatment (Table 2). This in-
cluded mitochondrial complex I enzyme ETFD and complex III enzymes ATPA and ATPG
the abundance of which were increased in L66 compared to wild-type. LMTM seems to
have a great impact on mitochondria (Supplementary Figure S4). LMTM acted mainly
on complexes I, III and V of the electron transport chain (ETC) in L66 mice but it also
reduced numerous enzymes involved in the TCA cycle and in fatty acid metabolism, e.g.,
AATM, ACADV, ACLY, BACH, ECHA, ECHB, THIM, ACON, DHE3, MDHM, ODO2 and
SUCA in support of mitochondrial recovery of function. In summary, LMTM induced the
NRF2-mediated antioxidant defence system and appeared to facilitate energy biogenesis
and mitochondrial function as suggested for the parent compound MTC [51,57].
Although not regulated between genotypes (Table 2), protein ubiquitination was
strongly modified by LMTM in L66 mice (Supplementary Figure S5). Ubiquitination in-
cludes several heat shock proteins (HSP), proteasome regulatory subunits (PSM), ubiquitin-
protein ligases and multiple chaperones that were all modulated by LMTM. Although their
role in AD and FTD is uncertain, chaperones like HSP74 and HS105 were decreased, while
STIP1 and HSP7C were increased suggesting that protein degradation is facilitated by
LMTM treatment. For the E3 ubiquitin-protein ligase RNF181, a RING-type E3 ubiquitin
transferase with a total of at least 23 proteins, species 8, 9 and 200 were increased more
than 1.5-fold (Supplementary Table S1). Three further RNF181 species (260, 283 and 305)
were lowered by LMTM, and they contained tau at very low abundance (between 0.5 and
4% of total spot volume, data not shown). These results support the notion that LMTM
induces or facilitates the degradation and removal of aggregated tau.
4. Discussion
In this study, we performed an unbiased proteomic investigation comparing brain
samples of wild-type and L66 tau-transgenic mice and assessed the ability of LMTM in
reversing these changes in L66. L66 harbours the FTD-associated mutation P301S in the
MAPT gene. These mice show early onset high tau load in hippocampal and cortical
neurons, a normal cholinergic phenotype, a robust neuroinflammation and sensorimotor
and motor learning deficits [40,42]. Several of these phenotypes, including tau pathology
and behavioural deficiencies, were reversed by treatment with LMTM [43,47]. We have
now extended these studies using a similar LMTM regime in L66 mice to identify key
pathways underlying these corrections. Since we have used whole brain extracts without
region-specificity, the alterations that we report for the brain proteome may have occurred
in neurons, astrocytes or both [38]. However, the changes are most likely associated
with neurons, since these cells account for around two-third of the different cell types in
the mouse brain [74], tau expressed in L66 mice is under the neurone-specific regulatory
element Thy1 [40], and tau aggregates are most prevalent in neurons in mutant tau mice [75]
and human tauopathies [76]. A limitation of this study, however, is that the resulting
proteomic analyses do not provide spatial resolution of FTD-related brain areas but rather
reflect changes that occur across the whole brain. in contrast to the recently preferred
LC-MS/MS techniques, we have separated protein species before digestion, identification
and quantification by 2-DE gel technology (for comparison see [24,77]), as it offers great
flexibility and tunable resolution, and enables the simultaneous analysis of the total protein,
protein species and post-translational modifications in large-scale studies including changes
with functional relevance to disease mechanisms [66,78–80].
The key findings that we report here are that mutant tau induced metabolic/mitochondrial
dysfunction, changes in synaptic transmission and stress responses and that LMTM recovered
these functions in a dose-independent manner. LMTM-activated pathways not affected by
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tau-overexpression included NRF2, oxidative phosphorylation and protein ubiquitination.
In contrast, LMTM did not recover trophic support and neuronal cell loss induced by the
expression of mutant tau.
4.1. L66 Mice Show Common Pathways Dysregulated in FTD Patients
Only a few proteomic studies are available for FTD (for review see [21,22]) and many
show a large overlap between FTD-tau, FTD-TDP43, AD and other neurodegenerative dis-
orders. Hu et al. identified 151 differentially regulated proteins, but these only yielded 78%
specificity for FTD-TDP43 over FTD-tau [26]. Others reported 56 differentially regulated
proteins and only 10 of these were different between the FTD-TDP43 and FTD-tau sub-
types [27]. Even fewer putative biomarkers (15) were revealed in a comparative study of
AD and FTD patients with only seven of these differentiating between both dementias [28]
suggesting that it will be difficult to achieve specificity in protein biomarkers for any one
form of dementia. This appears to hold, since spinal cord from FTD patients contained
52 dysregulated proteins compared to controls, but 33 of these were shared between FTD
and amyotrophic lateral sclerosis (ALS) and played a role in mitochondrial dysfunction
and metabolic impairment [23]. By contrast, disrupted protein synthesis and vesicle traf-
ficking [81], and synaptic transmission and inflammation [82] specifically changed in FTD
brains compared with progressive supranuclear palsy or ALS emphasising that different
alterations in protein content and activity might still be determined when studying very
selective dementia cohorts. Proteomics studies in experimental FTD models are limited
too. Using 2D-DIGE to investigate spinal cord tissue from 7-month-old P301S tau mice, the
antioxidant proteins peroxiredoxin-6, heat shock protein 2, apolipoprotein E and latexin
were all enhanced in astrocytes underlining a neuroprotective function of these cells [38,39].
Critically, few dysregulated protein network clusters including metabolic/mitochondrial,
synaptic transmission and stress responses seem to be commonly disrupted in experimental
and clinical FTD studies and indeed, these networks were amongst those dysregulated in
L66 and modified by LMTM.
4.2. Tau Accumulation in L66 Mice Affects Multiple Brain Proteome Networks
In our L66 mice, tau overexpression revealed a significant differential regulation of
about 3.5% of all spots (Experiment 1: 71 regulated spots out of around 2000 visible spots).
Of the dysregulated protein species, approximately 30% were metabolic, 13% belonged to
neurotransmission/neurodevelopment, while 9% were structural proteins and 12% played a
role in oxidative stress. Dysregulation of metabolic processes in general [83] and mitochondrial
function in particular [84] have been reported before for the brain proteome of P301L tau
mice. Immunoprecipitation combined with mass spectroscopy also revealed a reduction in
mitochondrial function, specifically in proteins involved in the ETC, together with an increase
in heat shock proteins. These findings correlated with the amount of tau load in neurons ([39];
this study) and are clearly in line with clinical investigations underpinning the suitability of
P301L/P301S mutant mice as a model for FTD. A presynaptic location for these changes is
further indicated by a decrease in amphiphysin-1 levels [85], a protein involved in clathrin-
mediated endocytosis [86–88], and in L66 mice were most likely due to the accumulation of
non-phosphorylated tau in the pre-synapse [41]. A complementary study on RNA profiling
conducted in young (2 months) and old (12 months) P301S mice found that most of the
differentially regulated genes were associated with synaptic signalling [75]. In their study,
gene-networks linked to pre-synaptic vesicle trafficking were altered throughout disease
progression, while gene-networks linked to the post-synapse, i.e., glutamate signalling, were
dysregulated in young but not in old mice. We only investigated 6-month-old L66 mice
but confirmed that levels of proteins for both synaptic vesicle trafficking (e.g., endocytosis,
transport and recycling of synaptic vesicles, see Table 1) and glutamate signalling (degradation
and biosynthesis of glutamate, see Table 2) were altered. Further, a recent study established
a negative correlation between tau and glutamate receptor activity in FTD patients with tau
mutations [89]. Taken together, these results provide compelling evidence that metabolic
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dysfunction, synaptic transmission and stress response pathways are a consistent phenotype
associated with overexpression of tau mutated at residue 301, and these changes match those
frequently reported in clinical studies. L66 mice, therefore, are an ideal translational model to
examine drug effects in preclinical conditions.
4.3. LMTM Corrects Metabolic Dysfunction, Synaptic Transmission and Stress Responses in
L66 Mice
LMTM is being developed as a treatment targeting pathological aggregation of tau
protein in AD and FTD [48,49,90,91], and this strategy appears promising since a correla-
tion between the degree of tau aggregation and the severity of dementia has been estab-
lished [12,13,37,45]. LMTM blocks tau aggregation in vitro [46,92], reverses behavioural
deficits in tau transgenic mice [47] and preserves cognitive decline and brain atrophy in
AD patients [48,49]. In addition, we have recently reported that LMTM restores acetyltrans-
ferase immunoreactivity in basal forebrain neurons, increases hippocampal acetylcholine
levels and complex IV activity in a mouse model of AD and normalises glutamate release
from synaptosomal preparations ex vivo [43,56]. We have previously reported significant
reductions in tau pathology and the correction of behavioural deficiencies in L66 mice
using a similar LMTM dosing regimen [47]. The main findings from the latter study were
the slightly higher overall reduction of tau-positive neurons for the 45 mg/kg dose of
LMTM, while behavioural correction of the motor phenotype on the rotating road was
fully recovered following administration of the lower 15 mg/kg dose (see Figures 7 and
9 in [47]). Our proteomics investigation, that also included 15 and 45 mg/kg LMTM,
revealed that 22% of all spots (433/2000) were regulated by LMTM and the majority of
these (95%) followed the same regulation pattern for both doses. These findings are in line
with behavioural analyses of L66 and with a recent pharmacokinetic study in AD and FTD
patients showing that the maximal effective dose for LMTM is at 16 mg per day for AD
and 20–60 mg per day for FTD, while higher doses are devoid of additional benefit [47–49].
In terms of dysregulated protein species, roughly 30% were metabolic, 14% belong to
neurotransmission/neurodevelopment, 23% were involved in protein transcription (tran-
scription/translation/biosynthesis/modification/degradation), while 6% played a role in
oxidative stress. From our pathway analyses, metabolic dysfunction, synaptic transmission,
and stress responses were altered due to tau expression and corrected/improved by LMTM,
underlining the pluripotent effect of the drug. While we have no confirmatory evidence,
we propose that effects of LMTM are most likely mediated indirectly by its mechanism as
a tau aggregation inhibitor as these pathways were altered by overexpression of mutant
tau. By contrast, other pathways that could mitigate detrimental effects of tau, but are
presumably mediated directly and not via tau dissolution are, for example, NRF2, oxidative
phosphorylation and protein ubiquitination (see below).
4.4. No Effect of LMTM on Trophic Support Networks
BDNF, which is known to promote neuronal survival, was reduced in L66 mice, in
line with reports in several neurodegenerative disorders in humans, including FTD [93].
In P301S mice, a BDNF-related mechanism by which tau induces neuronal dysfunction
has been established [94], while others have reported increased BDNF levels specifically
in astrocytes [75]. In L66, neither the reduced trophic support through BDNF nor the
neuronal degeneration were affected by LMTM. This clearly establishes specificity for the
mechanistic correction of LMTM although the reported MTC increase in BDNF in dopamin-
ergic neurons [95] was not specifically addressed here. A dose comparison between our
study and the work of Bhurtel and colleagues, however, confirmed that equivalent doses
had been used, but regimes and length of administration were different. Furthermore,
reduced trophic support through BDNF is often connected to a reduction in mTOR activity;
dysregulation (both, increase and decrease) of mTOR and associated pathways has been
widely reported in neurodegenerative disorders [96,97]. Our pathway analyses highlighted
significant alterations of BDNF/mTOR and downstream PI3K-AKT/70S6K (Tables 2 and 4,
respectively) and so the latter pathway was investigated in more detail. In L66, PI3K-AKT-
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mTOR and downstream kinases p70S6K and 4E-BP1 were decreased and ERK-GSK-3ß
was increased. And although a small reversal of ERK overactivation was achieved, no
effect on 70S6K and 4E-BP1 were noted following LMTM treatment. It appears, therefore,
that this rescue of ERK, or any cellular pathways other than BDNF that can lead to mTOR
activation [98,99], is unlikely to be a principle target for LMTM.
4.5. Tau Compromises Presynaptic Structures and Their Recovery by LMTM
Of particular interest are actions of LMTM on synaptic transmission and mitochon-
drial function (metabolism and stress). There were considerable changes in these categories
in L66 mice related to the overexpression of mutant tau. These pathways are tightly con-
nected [100,101] and mitochondria have an important role in the homeostatic regulation of
presynaptic function [102]. It has been shown recently that tau protein is bound to the mito-
chondrial outer membrane and also enters the intermembrane space of mitochondria [103].
PHF-tau can form complexes with the voltage-dependent anion selective channel protein
(VDAC) in the mitochondrial outer membrane, and also with ATP synthase subunit 9
and core protein 2 of complex III in the intermembrane space [104]. These interactions
are likely to be deleterious for electron transport in mitochondria, and we suspect that
LMTM recovers mitochondrial function by direct interference with oxidative phosphory-
lation; most likely, LMTM would serve as a redox cycler similar to its parent compound
MTC [52,53,105]. Furthermore, tau binding promotes presynaptic actin polymerisation to
crosslink synaptic vesicles, which strongly restricts their mobilisation and affects docking,
transport and fusion of synaptic vesicles and impairs neurotransmitter release [88]. LMTM
is predicted to normalise pre-synaptic structure/function by dissolution of oligomeric tau
enriched in the pre-synaptic compartment of L66 mice [41], and this may be aided by the
induction of clathrin-mediated endocytosis and protein ubiquitination. Although LMTM
did not seem to correct expression levels of individual synaptic structural proteins, an
overall functional rescue of synaptic function by LMTM has been established [43,56].
4.6. LMTM Promotes Antioxidant Response via NRF-2 Activation in a Tau-Independent Fashion
The ability of MTC to activate cellular defence mechanisms by activation of NRF2
has been revealed in vitro [106] and in ageing, and it is associated with the restoration of
deficient antioxidant defence proteins such as NRF1 and SOD2 [51]. In P301S mice, MTC
also reduced glutathione-induced stress, increased SODM (or SOD2) activity and activated
NRF2-mediated antioxidant responses [57]. We here confirm, in L66 mice, that proteins
downstream of NRF2 such as stress-induced-phosphoprotein 1 (STIP1), glutathione S-
transferase Mu 5 (GSTM5), glutathione S-transferase omega-1 (GSTO1), ubiquitin carboxyl-
terminal hydrolase 14 (UBP14), ferritin heavy chain (FRIH) and mitochondrial superoxide
dismutase (SODM), were increased up to more than 2-fold by LMTM. LMTM therefore,
similar to MTC, promotes cellular defence by activating the NRF2 system.
5. Conclusions
The mutant form of tau in L66 mice induced protein changes related to metabolic/mitochondrial
function, synaptic transmission and stress responses. These functions are common to transgenic
models and clinical FTD studies. LMTM recovered these functions in a dose-independent manner
and confirmed its effect on tau-related dysfunction. Furthermore, LMTM has activated pathways
that were unaffected by tau-overexpression. These included NRF2 antioxidant response, oxidative
phosphorylation and protein ubiquitination, but did not show activity towards functions involved in
trophic support and neuronal degeneration.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cells10082162/s1, Figure S1: Biological processes altered between genotypes and in drug
cohorts. Pie charts illustrating altered proteins organised by biological processes as found by panther
classification system database. These represent (A) the 123 protein species dysregulated in L66
compared to wild-types (experiment 1) and (B) the 657 protein species changing due to LMTM (ex-
periment 2). Figure S2: Clathrin-mediated endocytosis signalling. The clathrin-mediated endocytosis
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signalling pathway was altered in L66 (experiment 1) and regulated by LMTM (experiment 2) as
found using the IPA tool (see Table 2 for results). Proteins which were increased due to LMTM
are shown in red, and those which are decreased are shown in green. Figure S3: NRF2-mediated
oxidative stress response. This pathway was altered in L66 (experiment 1) and regulated by LMTM
(experiment 2) as found by IPA (see Table 2 for results). Proteins which were increased due to LMTM
are shown in red, and those which are decreased are shown in green. Figure S4: Mitochondrial
function. This pathway was altered in L66 (experiment 1) and regulated by LMTM (experiment 2) as
found using the IPA tool (see Table 2 for results). Proteins which were increased due to LMTM are
shown in red, and those which are decreased are shown in green. Figure S5: Protein ubiquitination
pathway. This pathway was regulated by LMTM (experiment 2) but did not differ between genotypes
(experiment 1) as found using the IPA tool (see Table 2 for results). Proteins which were increased
due to LMTM are shown in red, and those which are decreased are shown in green. Table S1: Raw
data and MS data for all 487 spots.
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2-DE: two-dimensional gel electrophoresis; 4E-BP1: eukaryotic translation initiation factor 4E-binding
protein 1; AD: Alzheimer’s disease; ADORA2A: adenosine A2a receptor; AGRP: agouti-related
protein; AKT: protein kinase B; AKT1: RAC-alpha serine/threonine-protein kinase; APP: amy-
loid precursor protein; ARX: homeobox protein ARX; BDNF: brain-derived neurotrophic factor;
CaMKII: Ca2+/calmodulin-dependent protein kinase II; CDK5: cyclin-dependent kinase 5; CDK5R1:
cyclin-dependent kinase 5 regulatory subunit 1; E2F1: E2F transcription factor 1; EIF2: eukary-
otic initiation factor 2; EIF2B2: eukaryotic translation initiation factor 2B subunit beta; ERK5: ex-
tracellular signal regulated kinase 5; ETC: electron transport chain; FAK: focal adhesion kinase;
FMR1: synaptic functional regulator FMR1; FTD: frontotemporal dementia; FTDP-17: frontotem-
poral dementia with parkinsonism linked to chromosome 17; GSK-3: glycogen synthase kinase
3; HSF1: heat shock factor protein 1; htau40: human tau with 441 amino acids; HTT: huntingtin;
IEF: isoelectric focusing; IGF-1: insulin-like growth factor 1; IPA: Ingenuity Pathway Analysis;
LMTM, N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); MARK2:
serine/threonine-protein kinase MARK2; MKNK1: MAP kinase-interacting serine/threonine-protein
kinase 1; MS: mass spectrometry; MT: methylthioninium, MTC: methylthioninium chloride; MTOR:
serine/threonine-protein kinase mTOR; MYO5A: unconventional myosin-Va; NOS2: nitric oxide
synthase, inducible; NRF2: nuclear factor (erythroid-derived 2)-like 2; P70S6K: ribosomal protein S6
kinase beta-1; PARK2: E3 ubiquitin-protein ligase parkin; PHF, paired helical filament; PPAR: peroxi-
some proliferator-activated receptors; PSD95: postsynaptic density protein 95; PSEN1: presenilin-1;
PTM: post-translational modification; RAC: Rho GTPase family; RTN4: reticulon-4; SEPT5: septin-
5; SLC18A3: vesicular acetylcholine transporter; SNAP25: synaptosomal-associated protein 25;
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SNCA: alpha-synuclein; PI3K: phosphatidylinositol-4,5-bisphosphate 3-kinase; PKC: protein kinase
C; PLCB4: 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4; SOD1: superoxide
dismutase [Cu-Zn]; tau (or MAPT): microtubule-associated protein tau; TrkB: tropomyosin receptor
kinase B; VAMP2: vesicle-associated membrane protein 2; VDAC, voltage-dependent anion channel;
YWHAG: 14-3-3 protein gamma; ZNF746: zinc finger protein 746.
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